These antibodies enhanced the adhesion between OPN and FLSs, increased the expression of inflammatory cytokines including IL-6, aggravated arthritis, and lowered the retention rate of TNF inhibitors in RA patients. This evidence concerns the gene SPP1 and rheumatoid arthritis.